Orexigen Therapeutics (OREX) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Orexigen Therapeutics (OREX) Misses Q2 EPS by 1c
August 6, 2015 10:58 AM EDT
Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and raised his price target on Orexigen Therapeutics (NASDAQ: OREX) to $21.00 (from $17.00), noting Contrave is gaining traction, with clouds clearing on commercial efforts.
Duncan commented, "Orexigen reported cash of $76.1M and 2Q15 US sales of Contrave at... More
August 6, 2015 7:00 AM EDT
Orexigen Therapeutics (NASDAQ: OREX) announced that wholly-owned subsidiary Orexigen Therapeutics Ireland Ltd. and Kwang Dong Pharmaceutical Company, Ltd. have executed a distributorship agreement for South Korea for Contrave® (naltrexone HCl / bupropion HCl extended release) monotherapy for weight management in overweight or obese adult... More
August 6, 2015 6:59 AM EDT
Orexigen Therapeutics (NASDAQ: OREX) and Takeda Pharmaceutical Company Limited announced execution of an amended and restated collaboration agreement that resolves all outstanding disputes between the companies and aligns the partnership for the continued long-term success of CONTRAVE.
"CONTRAVE has quickly established itself as the... More
